Literature DB >> 7812544

Decreased tobacco-glycoprotein-induced lymphocyte proliferation in vitro in pulmonary eosinophilic granuloma.

L H Youkeles1, J N Grizzanti, Z Liao, C J Chang, D L Rosenstreich.   

Abstract

Pulmonary eosinophilic granuloma is a disorder caused by localized collections of proliferating histiocytes in the lung. Little is known about its etiology except that the majority (58 to 97%) of patients are current or ex-smokers, making the potential etiologic role of tobacco products an important area for research. Tobacco glycoprotein (TGP) is a potent immunostimulator that has been isolated from cigarette smoke. TGP-specific lymphocyte proliferation, and cytokine production in vitro, were measured in three patients with pulmonary eosinophilic granuloma in remission and in three closely matched normal subjects with similar smoking histories. One patient with eosinophilic granuloma of bone and a matched control subject were also studied. Peripheral blood mononuclear cells were cultured with TGP, the recall antigen streptokinase (SK), and the mitogen concanavalin A (Con A). All three of the patients with pulmonary eosinophilic granuloma exhibited significant decreases in lymphocyte stimulation to TGP, despite normal responses to SK and Con A. In contrast, the response of the patient with eosinophilic granuloma of bone was higher than her matched control. The mean responses of the patients with pulmonary eosinophilic granuloma to TGP was significantly lower than the mean of nondiseased smokers or of normal nonsmokers. Twenty-four-hour culture supernatants were collected and assayed for cytokine levels (IL-1, IL-2, and IL-6). TGP-stimulated IL-2 production was significantly lower in the patients with pulmonary eosinophilic granuloma than in the normal subjects, confirming the reduced T-cell proliferative response.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7812544     DOI: 10.1164/ajrccm.151.1.7812544

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  8 in total

Review 1.  Adult pulmonary Langerhans' cell histiocytosis.

Authors:  A Tazi; P Soler; A J Hance
Journal:  Thorax       Date:  2000-05       Impact factor: 9.139

Review 2.  Rare lung diseases III: pulmonary Langerhans' cell histiocytosis.

Authors:  Stephen C Juvet; David Hwang; Gregory P Downey
Journal:  Can Respir J       Date:  2010 May-Jun       Impact factor: 2.409

Review 3.  [Pulmonary Langerhans cell histiocytosis].

Authors:  H H Popper
Journal:  Pathologe       Date:  2015-09       Impact factor: 1.011

4.  Complete disappearance of lung abnormalities on high-resolution computed tomography: a case of histiocytosis X.

Authors:  Sergio Negrin-Dastis; Dominique Butenda; Jacques Dorzee; Jacques Fastrez; Jean-Paul d'Odémont
Journal:  Can Respir J       Date:  2007 May-Jun       Impact factor: 2.409

5.  New insights into the molecular pathogenesis of langerhans cell histiocytosis.

Authors:  Francesca M Rizzo; Mauro Cives; Valeria Simone; Franco Silvestris
Journal:  Oncologist       Date:  2014-01-16

Review 6.  Cigaret smoking and the lung.

Authors:  S Murin; J Hilbert; S J Reilly
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 10.817

Review 7.  Langerhans cell histiocytosis.

Authors:  Joan Manel Gasent Blesa; Vicente Alberola Candel; Carlos Solano Vercet; Juan Laforga Canales; Christof Semler; Maria Rosa Pérez Antolí; Carlos Rodríguez-Galindo
Journal:  Clin Transl Oncol       Date:  2008-11       Impact factor: 3.340

Review 8.  Interstitial lung diseases-can pathologists arrive at an etiology-based diagnosis? A critical update.

Authors:  Helmut H Popper
Journal:  Virchows Arch       Date:  2012-12-07       Impact factor: 4.064

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.